Clinical Scorecard: Comparative Analysis of Initial Surgical Intervention versus Neoadjuvant Treatment in Pancreatic Cancer with Venous Involvement: A Multicenter Retrospective Study

At a Glance

Key Highlights

• Comparison of upfront surgery (US) versus neoadjuvant therapy (NAT) in pancreatic cancer patients with venous involvement.

• Higher rates of radical resection observed in the NAT group compared to the US group.

• Increased short-term morbidity associated with US, particularly in patients undergoing venous resection.

Guideline-Based Recommendations

Diagnosis

• Assessment of venous involvement via radiological imaging or intra-operative evaluation.

Management

• Consider neoadjuvant therapy for borderline resectable tumors with venous involvement.

Monitoring & Follow-up

• Follow-up on overall and disease-free survival post-surgery.

Risks

• Higher rates of complications and reoperations associated with upfront surgery.

Patient & Prescribing Data

690 patients treated with upfront surgery and 361 patients receiving neoadjuvant therapy.

Patients undergoing NAT had more favorable pathological outcomes compared to those receiving US.

Clinical Best Practices

• Utilize neoadjuvant therapy for patients with suspected venous involvement to improve surgical outcomes.

• Conduct thorough preoperative assessments to determine the extent of venous involvement.

Related Resources & Content

1. Comprehensive Review and Meta-Analysis of Modern Pancreatic Surgery Involving Arterial Resection, Springer, 2020 -- Title

2. Outcomes After Minimally Invasive vs Open Surgery for Pancreatic Adenocarcinoma, ASCO Post, 2023 -- Title

3. VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer, ASCO Post, 2026 -- Title

4. NCCN Guidelines Version 2.2025, NCCN -- Title

5. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer, PMC -- Title

6. Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter?, PubMed -- Title

7. the asco post — VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer

8. NCCN Guidelines Version 2.2025

9. Pan-Asian adapted ESMO Clinical Practice Guidelines

10. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy

11. Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter? - PubMed

12. Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequential analysis of randomized controlled trials - ScienceDirect

13. Neoadjuvant treatments for resectable (RPC) and borderline resectable pancreatic adenocarcinoma (BRPC): A pairwise and network meta-analysis (NMA). - ASCO

14. Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: A Systematic Review and Meta-Analysis - PMC